Table 6 Adverse events and early termination of Acthar gel treatment in patients with NS
From: Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series
Nephrotic syndrome etiology | Patients reporting treatment-related AEs, n (%) | Treatment-related AEs | Early termination due to AEsa, n (%) |
|---|---|---|---|
FSGS (n = 15) | 3 (20 %) | Increased swelling (n = 1) Hyperglycemia (n = 2) Hypertension (n = 1) Weight gain (n = 1) Upper respiratory infections (n = 1) | 1 (6.7 %) Edema 1 (6.7 %) Reason not given |
iMN (n = 11) | 4 (36.4 %) | Fatigue (n = 1) Dizziness (n = 1) Weight gain (n = 2) Hypokalemia (n = 1) | 1 (9 %) Fatigue |
IgAN (n = 5) | 1 (20 %) | Weight gain (n = 1) Hypertension (n = 1) | 1 (20 %) Weight gain, hypertension 1 (20 %) Patient decision |
DN (n = 4) | 3 (75 %) | Weight gain (n = 2) Hypertension (n = 1) Hyperglycemia (n = 1) Decreased bone mineralization (n = 1) | 1 (25 %) Weight gain, hypertension |
MLN (n = 2) | 0 | 0 | |
MCD (n = 2) | 0 | 0 | |
FGN (n = 1) | 0 | 0 | |
MPGN (n = 1) | 0 | 0 | |
Otherb (n = 3) | 2 (66.7 %) | Seizures (n = 1) Hyperglycemia (n = 1) Weight gain (n = 1) Hypertension (n = 1) | 1 (33.3 %) Seizures |